Exogenous TRAIL holds promise as a potential cancer therapeutic due to its selectivity for malignant cells with minimal toxicity against normal tissue [23], and its translational relevance has been increased by the development of new variants such as IZI1551 [24] and ABV-2661, a TRAIL-R agonist fusion protein [25] which is currently in a Phase 1 clinical trial for adult patients with previously-treated malignancies (NCT03082209). The gene discussed is TNFSF10; the disease is cancer.